GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SMS Pharmaceuticals Ltd (NSE:SMSPHARMA) » Definitions » Piotroski F-Score

SMS Pharmaceuticals (NSE:SMSPHARMA) Piotroski F-Score : 8 (As of Dec. 11, 2024)


View and export this data going back to 2007. Start your Free Trial

What is SMS Pharmaceuticals Piotroski F-Score?

Good Sign:

Piotroski F-Score is 8, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

SMS Pharmaceuticals has an F-score of 8. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for SMS Pharmaceuticals's Piotroski F-Score or its related term are showing as below:

NSE:SMSPHARMA' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 5   Max: 9
Current: 8

During the past 13 years, the highest Piotroski F-Score of SMS Pharmaceuticals was 9. The lowest was 3. And the median was 5.


SMS Pharmaceuticals Piotroski F-Score Historical Data

The historical data trend for SMS Pharmaceuticals's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SMS Pharmaceuticals Piotroski F-Score Chart

SMS Pharmaceuticals Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.00 8.00 6.00 4.00 8.00

SMS Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 8.00 - -

Competitive Comparison of SMS Pharmaceuticals's Piotroski F-Score

For the Drug Manufacturers - General subindustry, SMS Pharmaceuticals's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SMS Pharmaceuticals's Piotroski F-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, SMS Pharmaceuticals's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where SMS Pharmaceuticals's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Net Income was ₹498 Mil.
Cash Flow from Operations was ₹501 Mil.
Revenue was ₹7,065 Mil.
Gross Profit was ₹2,087 Mil.
Average Total Assets from the begining of this year (Mar23)
to the end of this year (Mar24) was (8796.101 + 10340.926) / 2 = ₹9568.5135 Mil.
Total Assets at the begining of this year (Mar23) was ₹8,796 Mil.
Long-Term Debt & Capital Lease Obligation was ₹1,221 Mil.
Total Current Assets was ₹5,339 Mil.
Total Current Liabilities was ₹3,317 Mil.
Net Income was ₹-71 Mil.

Revenue was ₹5,197 Mil.
Gross Profit was ₹1,291 Mil.
Average Total Assets from the begining of last year (Mar22)
to the end of last year (Mar23) was (8595.017 + 8796.101) / 2 = ₹8695.559 Mil.
Total Assets at the begining of last year (Mar22) was ₹8,595 Mil.
Long-Term Debt & Capital Lease Obligation was ₹1,217 Mil.
Total Current Assets was ₹4,106 Mil.
Total Current Liabilities was ₹2,549 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

SMS Pharmaceuticals's current Net Income (TTM) was 498. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

SMS Pharmaceuticals's current Cash Flow from Operations (TTM) was 501. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar23)
=498.26/8796.101
=0.05664555

ROA (Last Year)=Net Income/Total Assets (Mar22)
=-70.593/8595.017
=-0.00821325

SMS Pharmaceuticals's return on assets of this year was 0.05664555. SMS Pharmaceuticals's return on assets of last year was -0.00821325. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

SMS Pharmaceuticals's current Net Income (TTM) was 498. SMS Pharmaceuticals's current Cash Flow from Operations (TTM) was 501. ==> 501 > 498 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar23 to Mar24
=1220.863/9568.5135
=0.12759171

Gearing (Last Year: Mar23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar22 to Mar23
=1217.469/8695.559
=0.14001044

SMS Pharmaceuticals's gearing of this year was 0.12759171. SMS Pharmaceuticals's gearing of last year was 0.14001044. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar24)=Total Current Assets/Total Current Liabilities
=5338.948/3317.184
=1.60948202

Current Ratio (Last Year: Mar23)=Total Current Assets/Total Current Liabilities
=4106.486/2549.135
=1.61093312

SMS Pharmaceuticals's current ratio of this year was 1.60948202. SMS Pharmaceuticals's current ratio of last year was 1.61093312. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

SMS Pharmaceuticals's number of shares in issue this year was 84.652. SMS Pharmaceuticals's number of shares in issue last year was 84.652. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=2087.486/7064.565
=0.29548684

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=1291.391/5197.468
=0.24846541

SMS Pharmaceuticals's gross margin of this year was 0.29548684. SMS Pharmaceuticals's gross margin of last year was 0.24846541. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar23)
=7064.565/8796.101
=0.80314733

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar22)
=5197.468/8595.017
=0.60470712

SMS Pharmaceuticals's asset turnover of this year was 0.80314733. SMS Pharmaceuticals's asset turnover of last year was 0.60470712. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+1+0+1+1+1
=8

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

SMS Pharmaceuticals has an F-score of 8. It is a good or high score, which usually indicates a very healthy situation.

SMS Pharmaceuticals  (NSE:SMSPHARMA) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


SMS Pharmaceuticals Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of SMS Pharmaceuticals's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


SMS Pharmaceuticals Business Description

Traded in Other Exchanges
Address
Plot No. 72, H.No. 8-2-334/3&4, Road. No. 5, Opposite SBI Executive Enclave, Banjara Hills, Hyderabad, TG, IND, 500034
SMS Pharmaceuticals Ltd is a drug manufacturing company. It is engaged in the manufacturing and sale of active pharmaceutical ingredients (API's), and their intermediates viz. Metal Acetylacetonates, Diltiazem Hydrochloride and Taxol C-13 Side Chain. Its product portfolio includes drugs for anti-ulcer, anti-fungal, anti-migraine, anti-diabetic, erectile dysfunction, anti-viral, among others.

SMS Pharmaceuticals Headlines

No Headlines